Abstract 466P
Background
Brain stem tumors are among the most severe oncological diseases in children. The only real method of help remains radiation therapy, which makes it possible to alleviate the severity of neurological disorders, but for most patients, the effect achieved, regardless of the type of ionizing radiation used, is temporary and after various periods (from 3 months to several years), the tumor resumes growth. The main purpose of our work was to determine the possibilities and prospects of repeated radiation therapy in children with diffuse brain stem tumors.
Methods
In the period 1998-2022, analysis of short and long-term results of 132 children and adolescents with brainstem tumors treated at the Russian Scientific Center of Roentgenoradiology were evaluated. Out of 132 patients treated at RNCRR, 60 children were selected whose remission lasted more than 9 months and the Lansky scale of more than 40 points for re-irradiation.
Results
As a result of re-irradiation, out of 45 children with a Lansky status of 40-50 points, it was improved in 36 (80%). An additional 15 children were included in the group with an initial Lansky status of 70-90 points, initially represented by one child, and only 9 patients' condition worsened or did not change. The median life expectancy in the group of patients after one course of radiation therapy was 13.9 months, but in the group of those treated repeatedly - 22.6 months.
Conclusions
Re-irradiation using 30.0 to 45.0 Gy in standard fractionation in combination with adequate accompanying therapy in 90% of cases allows an increase in the remission period in dense tumors and temporarily improve the quality of life in cystic solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
469P - Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial
Presenter: Marie Porte
Session: Poster session 16
470P - Mitochondrial ribosomal proteins (MRPs) in glioblastoma multiforme: Omics approach
Presenter: Jehad Yasin
Session: Poster session 16
471P - PTEN alteration as a predictor of second-line efficacy in patients with recurrent IDHwt-glioblastoma
Presenter: Eugenia Cella
Session: Poster session 16
472P - Comprehensive quinomics assessment of BPM31510IV treatment in advanced glioblastoma multiforme patients
Presenter: Seema Nagpal
Session: Poster session 16
473P - A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)
Presenter: Maurizio Polano
Session: Poster session 16
474P - Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity
Presenter: kaijia zhou
Session: Poster session 16
Resources:
Abstract
475P - Optimising genomic testing for patients with central nervous system (CNS) tumours using oxford nanopore technology
Presenter: Alona Sosinsky
Session: Poster session 16
476P - The role of androgen receptor expression and epigenetic regulation in adult-type diffuse gliomas
Presenter: VINCENZO DI NUNNO
Session: Poster session 16
477P - ENHO's protective role in lower grade glioma
Presenter: Osama Younis
Session: Poster session 16
478P - Molecular characterization of adult non-glioblastoma central nervous system (CNS) tumors to identify potential targettable alterations
Presenter: Marta Padovan
Session: Poster session 16